Carbohydrate Structure of Erythropoietin Expressed in Chinese Hamster Ovary Cells by a Human Erythropoietin CDNA
Overview
Affiliations
The proper glycosylation of erythropoietin is essential for its function in vivo. Human erythropoietins were isolated from Chinese hamster ovary cells transfected with a human erythropoietin cDNA and from human urine. Carbohydrate chains attached to these proteins were isolated and fractionated by anion-exchange high performance liquid chromatography (HPLC) and HPLC employing a Lichrosorb-NH2 column. The structures of fractionated saccharides were analyzed by fast atom bombardment-mass spectrometry and methylation analysis before and after treatment with specific exoglycosidases. Both erythropoietins were found to contain one O-linked oligosaccharide/mol of the proteins, and its major component was elucidated to be NeuNAc alpha 2----3Gal beta 1----3(NeuNAc alpha 2----6)GalNAcOH (where NeuNAc represents N-acetylneuraminic acid) in both proteins. The N-linked saccharides of recombinant erythropoietin were found to consist of biantennary (1.4% of the total saccharides), triantennary (10%), triantennary with one N-acetyllactosaminyl repeat (3.5%), tetraantennary (31.8%), and tetraantennary with one (32.1%), two (16.5%), or three (4.7%) N-acetyllactosaminyl repeats. All of these saccharides are sialylated by 2----3-linkages. Tetraantennary with or without polylactosaminyl units are mainly present as disialosyl or trisialosyl forms, and these structures exhibit the following unique features. alpha 2----3-Linked sialic acid and N-acetyllactosaminyl repeats are selectively present in the side chains attached to C-6 and C-2 of 2,6-substituted alpha-mannose and C-4 of 2,4-substituted alpha-mannose. We have also shown that the carbohydrate moiety of urinary erythropoietin is indistinguishable from recombinant erythropoietin except for a slight difference in sialylation, providing the evidence that recombinant erythropoietin is valuable for biological as well as clinical use.
Leprovost S, Plasson C, Balieu J, Walet-Balieu M, Lerouge P, Bardor M Plant Biotechnol J. 2024; 22(11):3018-3027.
PMID: 38968612 PMC: 11500980. DOI: 10.1111/pbi.14424.
An etanercept O-glycovariant with enhanced potency.
Biel T, Faison T, Matthews A, Zou G, Ortega-Rodriguez U, Pegues M Mol Ther Methods Clin Dev. 2022; 25:124-135.
PMID: 35402630 PMC: 8957051. DOI: 10.1016/j.omtm.2022.03.002.
Modified recombinant human erythropoietin with potentially reduced immunogenicity.
Susantad T, Fuangthong M, Tharakaraman K, Tit-Oon P, Ruchirawat M, Sasisekharan R Sci Rep. 2021; 11(1):1491.
PMID: 33452310 PMC: 7810742. DOI: 10.1038/s41598-020-80402-1.
Large-scale site-specific mapping of the O-GalNAc glycoproteome.
Yang W, Song A, Ao M, Xu Y, Zhang H Nat Protoc. 2020; 15(8):2589-2610.
PMID: 32681153 PMC: 8620167. DOI: 10.1038/s41596-020-0345-1.
Kaltashov I, Bobst C, Pawlowski J, Wang G J Pharm Biomed Anal. 2020; 184:113169.
PMID: 32092629 PMC: 7162711. DOI: 10.1016/j.jpba.2020.113169.